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Basic Investigations 
 
Effects of Dan Wei Powder (㚚㚗ᬷ) Tea Bag on Aggregation of Blood 
Platelet in vivo and in vitro 
 
YU Cheng-lieֲᡓ⚜ 1, SHOU Qi-yangᇓ᮫ᡀ 2, ZHU Guang-yaᴅᑓѮ 1, YU Guo-youԭ೑ট 3,  
XIE Ri-qing䇶᮹䴦 2, JIA Lin-chao䌒Ј䍙 2, and ZHOU Wei-min਼ि⇥ 2 
 
 
Objective: To observe effects of Dan Wei Powder (㚚㚗ᬷ Powder for treating the gall bladder and stomach) Tea 
Bag (DWSTB) on the aggregation rate of blood platelet in vivo and in vitro.  
Methods: Increase of the platelet aggregation rate in the rat in vivo was induced by carrageenin, and increase of the 
rabbit platelet aggregation rate in vitro was induced by adenosine diphosphate (ADP) and collagen, respectively. 
The effects of DWSTB on the platelet aggregation rate were investigated in vivo and in vitro, respectively.  
Results: The maximum in vivo platelet aggregation rate in the rat was significantly decreased after administration 
of 2.0 and 4.0 g•kg-1 DWSTB (P<0.05.P<0.01). The maximum rabbit platelet aggregation rate induced by ADP and 
collagen in vitro were suppressed significantly by 2.0–16.0 mg·mL-1 and 2.0–8.0 mg·mL-1 DWSTB, respectively 
(P<0.05.P<0.01). And the effect of DWSTB on platelet aggregation was raised with increase of its dose.  
Conclusion: Dan Wei Powder Tea Bag can restrain the aggregation of platelet in vivo and in vitro.  
Keywords: Dan Wei Power Tea Bag (DWSTB); aggregation of blood platelet; carrageenin; adenosine diphosphate 
(ADP); collagen 
Dan Wei Powder (㚚㚗ᬷ Powder for treating the gall 
bladder and stomach DWSTB), a new modified Si Ni 
Power (ಯ䗚ᬷ Powder for Treating Cold limbs), is 
composed of the recipe Si Ni San in Shang Han Lun (Ӹ
ᆦ䆎 Treatise on Febrile Diseases) added with Pu Gong 
Ying (Herba Taraxaci), Xu Chang Qing (Radix Cynanchi 
Paliculati) and Mei Gui Hua (Flos Rosae Rugosae), etc. 
Clinically, Dan Wei Powder Decoction has a certain 
therapeutic effect, so the decoction is made into a new 
form of tea bag. DWSTB has obvious clinical therapeutic 
effects in treatment of gallbladder and stomach diseases 
with incoordination between the liver and the stomach, 
and diseases of both gallbladder and stomach,1 and in 
previous pharmacologic experiment it was found that 
DWSTB had inhibitory action on the platelet aggregation 
rate in the normal rat.2 In order to verify further the 
inhibitory action of DWSTB on platelet aggregation, 
effects of DWSTB on platelet aggregation were 
investigated in vivo and in vitro. 
METHODS 
Drugs 
DWSTB, 2.0 g crude drugs/bag, brown solid granules, 
lot No.20080616, were kept at normal temperature and 
dry place. Method of preparation: For in vivo experiment, 
20 g DWSTB was added with 100 mL distilled water of 
90–9 5ć, infusing for 15 min and filtered with clear 
gauze and pressed, and then the 0.2 g.mL-1 drug solution 
was diluted 0.1 and 0.05 g·mL-1, respectively, just before 
use; For in vitro experiment, 8 g DWSTB was added 
with 100 mL distilled water of 90–95ć, infusing for 15 
min, and filtered with gauze and pressed, the 80 mg·mL-1 
drug solution was diluted 2.5, 5.0, 10, 20, and 40 
mg·mL-1 drug solution, respectively, just before use. 
Aspirin enteric tablet was produced by Nanjing 
Baijingyu Pharmaceutical Co. Ltd., 25 mg × 100 
pieces/bottle, batch No: 071014. 
Experimental Animals1 
SD rats, male, SPF grade, weighing 220–240 g, were 
supplied by Shanghai Test Center of Laboratory Animals, 
Chinese Academy of Sciences / Shanghai Shikelai 
Experimental Animals Co., production license (SCXK 
(≾)2003-0003); Japanese White Rabbits, male, common 
grade, weighing 2.0–2.2 kg, were supplied by Shangyu 
City Xinghuo Rabbits Farm, production license (SCXK 
(⌭) 2008–0036).  
Main Instruments and Reagents 
Model 530 blood-platelet aggutometer (CHRONO- LOG 
Co., USA); DL-5-B centrifuge (Shanghai Anting 
Scientific Instrument Factory); FA1004 analytical 
balance (Shanghai Balance Instrument Factory); 725 
lower-temperature refrigerator (-86ć  FORMA Co., 
USA). 
Carrageenin (Sigma, 100 g/bottle, Lot No: 117H0151);  
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ADP (CHRONO-LOG, Lot No: 3373 12/07); sodium 
citrate (AR grade, 500 g/bottle, Shanghai 1st Reagents 
Factory, 2000-07-01); collagen (self-preparation): The 
external skin was taken from the tail of rat, with the scale 
and hypodermal fat removed, and cut into small pieces 
and then was added with saline in 1:9 ratio and ground at 
4ć  ill the solution showing cream color, and cen- 
ifuged at 3000 r/min for 10 min. The supernatant was 
10% collagen; platelet diluent (ammonium oxalate 
solution): 1.0 g ammonium oxalate was added with 
distilled water till 100 mL and filtrated ,and then kept at 
4ć. 
Condition of Animal Rooms 
SPF grade rat breeding room and normal grade rabbit 
breeding room, temperature 22±1ć, relative humidity 
50%–70%, ventilation times 15–20 times/h, light 
150–200 Lx, 12 h light-dark alternation, noise <50 dB, 
with an automatic controlling and displaying systems of 
temperature, humidity, light, pressure gradient, etc. 
Detection of Effects of DWSTB on in vivo Platelet 
Aggregation Rate in Rats 
Sixty SD male rats, weighing 220–240 g, were uniform 
divided according to body weight into 6 groups, n=10, 
normal group, model group, low dose group (DWSTB 
1.0 g·kg-1), middle dose group (DWSTB 2.0 g·kg-1), 
high dose group (DWSTB 4.0 g·kg-1), positive control 
group (aspirin 0.1 g·kg-1). The medicines (20 mL·kg-1) of 
corresponding concentrations were gastrically admin- 
istrated once each day, for 8 consecutive days. On the 7th 
day of administration, the rats in all the groups, except 
the normal group, were injected into the subcutaneous 
part of right posterolateral toes with 0.1 mL 1% 
carragreenin for inducing inflammation. On the 8th day, 
30 min after administration the rat was anesthetized with 
3% pentobarbital sodium (45 mg/kg). The blood was 
taken from abdominal vein and immediately poured into 
a tube containing 1h109 mmolgL-1 sodium citrate 
(blood: anticoagulant = 9:1), and then centrifuged at 
1000 r/min for 10 min. The supernatant was the plasma 
with rich platelet (PRP), and the residual blood was 
centrifuged at 3000 r/min for 10 min, the supernatant 
was plasma with poor platelet (PPP). Aggregation rates 
of PPP and PRP were respectively detected in Model 530 
platelet aggutometer. PPP and PRP 200 mL each was 
respectively poured into a turbidimetric tube and placed 
in a preheating hole. After incubation at 37ć for 10 min, 
the platelet aggregation was determined. In the detection, 
the PPP tube was used to set 100% reading and PRP to 
zero. Then 2.5 ȝL ADP inducer at final concentration of 
10 ȝmol/L was added to the PRP tube under stirring by a 
magnetic bar, the aggregation curve was recorded and the 
maximum platelet aggregation rate was calculated.3 
Detection of Effects of DWSTB on in vitro Platelet 
Aggregation Rate  
Blood was taken with a mono-use injector of 50 mL from 
the hearts of 6 Japanese White Rabbits in a spinal 
position, 30–40 mL each rabbit, and poured into a tube 
containing 3.8% sodium citrate (blood: anticoagulant = 
9:1) and sealed, and repeatedly turned over 5 times for 
full mixture, and then centrifuged at 1000 r/min for 10 
min, the supernatant was PRP, and other residual blood 
was centrifuged at 3000 r/min for 10 min, the 
supernatant was PPP. Platelet was counted with 
ammonium oxalate method. Twenty ȝL PRP was added 
to a clear tube with 0.38 mL platelet diluent and fully 
mixed, one drop of which was dripped into a well of a 
platelet counter, resting for 10 min for sediment of 
platelet. The platelet was counted under a high powder 
microscope. The counts of PRP was diluted with PPP as 
300×109 · L-1. PPP and PRP 200 ȝL each was 
respectively poured into a turbidimetric tube and placed 
in a preheating hole in Model 530 platelet aggutometer; 
For the blank control group, 50 ȝL 0.9% saline was 
added to the PRP tube; In the ADP-induced platelet 
aggregation experiment, 5.0, 10, 20, 40, 80 mg · mL-1 
DWSTB 50 ȝL each was respectively added into the 
DWSTB 1, 2, 3, 4, 5 dose groups, and the final 
concentration of DWSTB dose groups was respectively 
1.0, 2.0ǃ4.0ǃ8.0ǃ16.0 mg · mL-1 ;In the collagen-induced 
platelet aggregation experiment, 2.5, 5.0, 10, 20, 40 
mg · mL-1 DWSTB 50 ȝL each, was respectively added 
into PRP tubes in the DWSTB dose groups 1, 2, 3, 4, 5, 
50 ȝL, and the final concentration was respectively 0.5, 
1.0, 2.0, 4.0, 8.0 mg·mL-1; For the positive control group, 
50 ȝL of 1.0 mg · mL-1 aspirin was added into the PRP 
tube with the final concentration of 0.2 mg·mL-1. After 
incubation at 37ć for 10 min, the platelet aggregation 
was determined in the all groups. In the detection, the 
PPP tube was used to set 100% reading and PRP tube to 
zero. Then 5 ȝL ADP at final concentration of 13.3 
ȝmol/L or 10 ȝL 10% collagen was added to the PRP 
tube in final concentration of 10 ȝmol/L with stirring by 
a magnetic bar, and the aggregation curves were recorded. 
Repeat 8 times each group, The platelet aggregation rate 
was calculated according to the formula: Platelet 
aggregation inhibiting rate = (the inhibiting rate in the 
blank control group  the inhibiting rate in the 
medication group) / the inhibiting rate in the blank 
control group × 100%.4 
Statistical Analysis  
SSPS11.0 was used for statistical analysis of data, and all 
data were expressed as xfs. Measurement data were 
assessed with t test.  
RESULTS 
Effects of DWSTB on in vivo Platelet Aggregation 
Rate in Rats 
It can be seen from Table 1 that compared with the 
normal control group, the maximum platelet aggregation 
rate increased significantly (P<0.01) in the model group 
24 h after carrageenin-induced inflammation; Compared 
with the model group, the platelet aggregation rate in the 
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high dose DWSTB, middle dose DWSTB and positive 
control groups significantly decreased (P<0.05 or 
P<0.01), and did not significantly change in the low dose 
DWSTB group (P>0.05). 
Table 1. Effects of DWSTB on in vivo platelet aggregation rate in rats (n=10, xfs) 
Group Dose Maximum aggregation rate of platelet (%) 
Normal 20 mL·kg-1 distilled water 48.13±10.47 
Model   20 mL·kg-1 distilled water  63.20±5.25ƸƸ 
Low dose 1.0 g·kg-1 DWSTB 60.44±11.26 
Middle dose 2.0 g·kg-1 DWSTB  55.00±10.35* 
High dose   4.0 g·kg-1 DWSTB  50.60±9.45** 
Positive control 0.1 g·kg-1 Aspirin  31.60±11.63* 
Notes: Compared with the normal group, ƸƸP<0.01; Compared with the model group, *P<0.05, **P<0.01. 
Effects of DWSTB on ADP-induced in vitro Platelet 
Aggregation  
It is shown in Table 2 that after the rabbit platelet of the 
blank control group was induced by ADP, the maximum 
platelet aggregation rate was 64.75%; After addition of 
different doses of DWSTB and positive control aspirin, 
the ADP-induced maximum aggregation rate decreased 
to varying degrees. The maximum inhibiting rate 
decreased by 15.44%, 25.87%, 30.50%, 41.89%, and 
72.01%, respectively, by addition of 2.0 mg · mL-1, 4.0 
mg · mL-1, 8.0 mg · mL-1, 16.0 mg · mL-1 DWSTB, and 
5.0 mg · mL-1 aspirin (P<0.05, or P<0.01). The anti- 
platelet in vitro aggregation effect of DWSTB was 
strengthened with increase of the DWSTB dose. 
Table 2. Effects of DWSBD on ADP-induced in vitro platelet aggregation rate˄n=8, xfs) 
Group Concentration of drug Maximum aggregation rate of platelet (%) Inhibiting rate of platelet aggregation (%) 
Blank control ˉ 64.75±6.58  
Dose 1 1.0 mg·mL-1 64.00±8.42 1.16 
Dose 2   2.0 mg·mL-1   54.75±5.01** 15.44 
Dose 3 4.0 mg·mL-1    48.00±13.36** 25.87 
Dose 4 8.0 mg·mL-1    45.00±14.73** 30.50 
Dose 5   16.0 mg·mL-1    37.63±15.81** 41.89 
Positive control  Aspirin   18.13±5.94** 72.01 
Note: Compared with the blank control group, **P<0.01. 
 
Effects of DWSTB on collagen-induced in vitro 
platelet aggregation 
Table 3 indicates that after the rabbit platelet of the 
control group was induced by collagen, the maximum 
aggregation rate was 61.75%; After addition of different 
doses of DWSTB and positive control aspirin, the 
collagen-induced maximum aggregation rate decreased 
to varying degrees. The maximum inhibiting rate 
decreased by 18.99%, 52.70%, 85.18%, and 46.00%, 
respectively, by addition of 2.0 mg·mL-1, 4.0 mg·mL-1, 
8.0 mg · mL-1 DWSTB, and 0.25 mg · mL-1 aspirin (all 
P<0.01). The anti-platelet in vitro aggregation effect of 
DWSTB was strengthened with increase of the dose of 
DWSTB. 
Table 3. Effects of DWSBD on collagen-induced in vitro platelet aggregation rate (n=8, xfs) 
Group Concentration of drug Maximum aggregation rate of 
platelet (%) 
Inhibiting rate of platelet 
aggregation (%) 
Blank control ˉ 61.57±9.73  
Dose 1   0.5 mg·mL-1  60.50±10.17 1.74 
Dose 2 1.0 mg·mL-1 58.00±5.45 5.80 
Dose 3   2.0 mg·mL-1  49.88±7.94* 18.99 
Dose 4   4.0 mg·mL-1   29.13±4.67** 52.70 
Dose 5 8.0 mg·mL-1    9.13±5.06** 85.18 
Positive control Aspirin   33.25±6.82** 46.00 
Notes: Compared with the blank control group, *P<0.05, **P<0.01. 
DISCUSSION 
The recipe Si Ni Powder in the Shang Han Lun has been 
one of the clinically commonly-used prescriptions ever 
since ancient times. From the literatures of clinical 
application and experimental studies in recent years it is 
known that this recipe is perfect in combination of 
formula, and it has quite wide indications with 
modification according to different syndrome, with rapid 
therapeutic effects. Pharmacological studies indicate that 
it has functions of spasmolysis, anti-inflammation, 
analgesia, anti-ulcer, regulating vegetative nerve function, 
and promoting intestinal peristalsis, etc. All syndromes 
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induced by persistent and severe emotional changes, 
abnormal flow of liver-qi, or stagnation of liver 
combined with qi or blood stagnation, phlegm or food 
retention, fire or dampness, resulting in complicated and 
synthetic pathogenesis of liver, gallbladder , and spleen, 
stomach or other Zangfu organs, can be treated with 
modified Si Ni Powder. The indication of this recipe is 
fairly wide with clinical application far over the category 
of syndromes treated by “Si Ni” in the original text.5 
According to the theories of Zangfu organs and qi 
activities of ascending and descending in TCM, the new 
modified Si Ni Powder is composed of Si Ni Powder 
added with Pu Gong Ying (Herba Taraxaci), Xu Chang 
Qing (Radix Cynanchi Paliculati) and Mei Gui Hua (Flos 
Rosae Rugosae). In the recipe, Pu Gong Ying functions 
removing pathologic heat and toxic substances, rein- 
forcing spleen and stomach; Mei Gui Hua has functions 
of regulating the flow of qi to alleviate mental depression, 
and regulating blood flow to dissipate blood stasis; Xu 
Chang Qing has the effect of expelling wind to kill pain.6 
On the basis of clinical application and after achieving a 
certain therapeutic effects, the decoction is processed to a 
new form of tea bag. Thus, the functions of regulating 
the flow of qi to alleviate mental depression, str- 
engthening spleen and regulating stomach, regulating the 
flow of qi in traditional medicine are organically 
combined with antisepsis, anti-inflammation, promoting 
healing of gastric mucosa, inhibiting smooth muscle 
activity, alleviating gastrointestinal spasm and regulating 
vegetative nerve function in modern medicine, com- 
plementing each other. In preliminary pathological 
experiment, it was found that DWSTB also had function 
of inhibiting platelet aggregation of normal rats.2 
Platelet is a kind of blood cells with many physiologic 
functions, such as adhesion, aggregation, release, blood 
coagulation, thrombosis and clot retraction.7 It plays an 
important role in physiologic hemostasis and hemopathic 
course. Aggregation of a great number of platelet can 
induce failure of blood in free flow and thrombus. 
Platelet aggregation is regulated by prostaglandin-TXA 
system and cAMP system. Adhesion of collagen with 
platelet adhesion, and promoted platelet aggregation are 
a very complicated physiological course, in which 
glycoprotein (GP) is a dependent factor. At present, study 
holds that GP Ia/ĊaˈGPČˈGPĎ  are important 
collagen receptors. Combination of platelet GP Ia/IIa 
with collagen Ċ-CB3 makes platelet adhere to collagen, 
being early action. While collagen can indirectly 
combine with platelet through vWF-GP Ib, GP IIb/IIIa. 
Combination of platelet GP Ia/IIa with collagen can 
induce change of platelet form, but the way of action and 
signal conduction principle remain to be further studied.8 
ADP is a weak activator of platelet, when platelet is 
stimulated by other stimulators such as thrombase and 
collagen, ADP at molar concentration in platelet dense 
granules is released, so as to induce the strong second 
aggregation through stimulating platelet to release Ca2+ 
of low concentration (μM level). At the same time, ADP 
also induces rapid inflow of extracellular calcium. This 
extracellular mediator is considered a ligand of 
regulating calcium pathway. The patient with defect of 
ADP receptor or lack of ADP in platelet granules has 
tendency to hemorrhage. ADP receptor is a potential 
action target of anti-thrombus drugs.9 It was found that 
4.0, 2.0 g·kg-1 DWSTB could significantly decrease in 
vivo platelet aggregation rate in the rat, and 2.0–16.0 
mg·mL-1 DWSTB and 2.0–8.0 mg·mL-1 DWSTB could 
significantly reduce the ADP-induced maximum rabbit 
platelet aggregation rate, and the collage-induced 
maximum rabbit platelet aggregation in vitro, res- 
pectively, and the effects of anti-platelet aggregation in 
vivo and in vitro were strengthened with increase of 
DWSTB dose, indicating that DWSTB has obvious 
function of anti-platelet aggregation. 
Modern medicine holds that blood flow has important 
effects on activation, adhesion, aggregation and release 
of platelet.10 DWSTB has functions of soothing the liver 
and regulating the circulation of qi, regulating blood flow 
and removing blood stasis, which are possibly the 
mechanisms of DWSTB in anti-platelet aggregation in 
vivo and in vitro. 
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